Edward Mayerson

718 total citations
14 papers, 259 citations indexed

About

Edward Mayerson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Edward Mayerson has authored 14 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Edward Mayerson's work include Peptidase Inhibition and Analysis (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Bone health and treatments (3 papers). Edward Mayerson is often cited by papers focused on Peptidase Inhibition and Analysis (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Bone health and treatments (3 papers). Edward Mayerson collaborates with scholars based in United States. Edward Mayerson's co-authors include Sandip Pravin Patel, Elad Sharon, Young Kwang Chae, Melissa Plets, Razelle Kurzrock, Megan Othus, Charles D. Blanke, Christine M. McLeod, Christopher W. Ryan and Rashmi Chugh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Edward Mayerson

13 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edward Mayerson United States 7 211 110 75 49 44 14 259
Shagufta Shaheen United States 6 110 0.5× 45 0.4× 26 0.3× 24 0.5× 25 0.6× 34 231
Elise F. Nassif United States 9 159 0.8× 192 1.7× 34 0.5× 10 0.2× 51 1.2× 37 305
Daisuke Takayanagi Japan 11 245 1.2× 143 1.3× 69 0.9× 29 0.6× 8 0.2× 35 384
C Antonescu United States 8 86 0.4× 165 1.5× 47 0.6× 56 1.1× 44 1.0× 11 259
Marta Peri Italy 8 180 0.9× 73 0.7× 45 0.6× 12 0.2× 9 0.2× 19 289
Kenta Nio Japan 7 117 0.6× 37 0.3× 39 0.5× 11 0.2× 10 0.2× 28 169
Brian Quigley United States 9 165 0.8× 58 0.5× 59 0.8× 13 0.3× 13 0.3× 17 241
Alesha A. Thai Australia 9 230 1.1× 92 0.8× 71 0.9× 27 0.6× 3 0.1× 16 316
Justine Gantzer France 9 83 0.4× 114 1.0× 22 0.3× 22 0.4× 9 0.2× 34 241
Heejung Chae South Korea 9 168 0.8× 77 0.7× 35 0.5× 44 0.9× 3 0.1× 45 257

Countries citing papers authored by Edward Mayerson

Since Specialization
Citations

This map shows the geographic impact of Edward Mayerson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Mayerson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Mayerson more than expected).

Fields of papers citing papers by Edward Mayerson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Mayerson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Mayerson. The network helps show where Edward Mayerson may publish in the future.

Co-authorship network of co-authors of Edward Mayerson

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Mayerson. A scholar is included among the top collaborators of Edward Mayerson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Mayerson. Edward Mayerson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
Vaishampayan, Ulka N., Catherine M. Tangen, Abhishek Tripathi, et al.. (2022). SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. Journal of Clinical Oncology. 40(6_suppl). TPS402–TPS402. 7 indexed citations
4.
Lara, Primo N., Edward Mayerson, Erik Gertz, et al.. (2022). Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.. Journal of Clinical Oncology. 40(16_suppl). 5071–5071. 2 indexed citations
5.
Zhen, David B., Edward Mayerson, E. Gabriela Chiorean, et al.. (2022). SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).. Journal of Clinical Oncology. 40(16_suppl). TPS4179–TPS4179. 2 indexed citations
6.
Wagner, Michael J., Megan Othus, Sandip Pravin Patel, et al.. (2021). Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). Journal for ImmunoTherapy of Cancer. 9(8). e002990–e002990. 106 indexed citations
7.
Patel, Sandip Pravin, Edward Mayerson, Young Kwang Chae, et al.. (2021). A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort. Cancer. 127(17). 3194–3201. 74 indexed citations
8.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2020). Abstract 3418: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort. Cancer Research. 80(16_Supplement). 3418–3418. 5 indexed citations
9.
Wagner, Michael, Megan Othus, Sandip Pravin Patel, et al.. (2020). 795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). SHILAP Revista de lepidopterología. A475–A475. 9 indexed citations
10.
Adams, Sylvia, Megan Othus, Sandip Pravin Patel, et al.. (2020). Dual anti-CTLA-4 and anti-PD-1 blockade in metaplastic carcinoma of the breast: Dart (SWOG S1609, Cohort 36).. Journal of Clinical Oncology. 38(15_suppl). 1073–1073. 21 indexed citations
11.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2020). Abstract 3417: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort. Cancer Research. 80(16_Supplement). 3417–3417. 5 indexed citations
12.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2020). 270 A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the thyroid tumor cohort. SHILAP Revista de lepidopterología. A161.1–A161. 2 indexed citations
13.
Patel, Sandip Pravin, Megan Othus, Young Kwang Chae, et al.. (2019). SWOG 1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.. Journal of Clinical Oncology. 37(15_suppl). TPS2658–TPS2658. 13 indexed citations
14.
Zeig‐Owens, Rachel, Mayris P. Webber, Yang Liu, et al.. (2016). Agreement between Self-Reported and Confirmed Cancer Diagnoses in New York City Firefighters and EMS Workers, 2001–2011. Public Health Reports. 131(1). 153–159. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shagufta Shaheen Breakdown of academic impact, for papers by Elise F. Nassif Breakdown of academic impact, for papers by Daisuke Takayanagi Breakdown of academic impact, for papers by C Antonescu Breakdown of academic impact, for papers by Marta Peri Breakdown of academic impact, for papers by Kenta Nio Breakdown of academic impact, for papers by Brian Quigley Breakdown of academic impact, for papers by Alesha A. Thai Breakdown of academic impact, for papers by Justine Gantzer Breakdown of academic impact, for papers by Heejung Chae
Rankless by CCL
2026